NTase05 cGAMP Biosynthesis for cGAS-Independent STING Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a simple, inexpensive, and effective system to biosynthesize 2′3′-cGAMP independent of cGAS-directed synthesis, which can be isolated and used as a therapeutic compound, and for a host cell that can biosynthesize and deliver 2′3′-cGAMP to activate the STING pathway in vivo.
Innovation Solution
The synthesis of 2′3′-cGAMP is achieved through the action of nucleotidyltransferase (NTase05) enzymes, which catalyze the production from ATP and GTP components, and can be expressed in host cells or administered as a pharmaceutical composition to activate the STING pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If cGAS-directed synthesis is used to produce 2'3'-cGAMP, then the pathway is biologically regulated, but the system is complex and cannot be independently controlled for therapeutic purposes
Solution Approach 1:
The patent extracts the catalytic function of cGAS and transfers it to a heterologous host cell (bacteria) that expresses the cGAS enzyme or the NTase05 enzyme. This separates the 2'3'-cGAMP production function from the mammalian cGAS pathway, enabling independent control and therapeutic application without relying on the complex mammalian immune system.
Solution Approach 2:
The patent introduces bacteria as an intermediary system that can be genetically engineered to produce 2'3'-cGAMP. These bacteria serve as living factories that convert precursors into the therapeutic cyclic dinucleotide, which is then secreted or delivered to activate STING pathways in host animals.
2Ease of manufacture
If chemical synthesis methods are used to produce 2'3'-cGAMP, then independent production is achieved, but the process is expensive and complex
Solution Approach 1:
The patent employs bacteria that express NTase05 enzyme to catalyze the formation of 2'3'-cGAMP from simple precursor molecules (nucleotide triphosphates). The bacterial system performs the synthesis autonomously using its metabolic pathways, eliminating the need for complex multi-step chemical synthesis procedures and reducing production costs.
Solution Approach 2:
The patent replaces complex chemical synthesis machinery with a biological system (bacterial cells expressing NTase05). The enzyme-catalyzed reaction in bacteria substitutes for elaborate chemical synthesis protocols, providing a simpler, more scalable, and cost-effective production method.
3Ease of operation
If host cells are engineered to biosynthesize 2'3'-cGAMP, then in vivo delivery is enabled, but genetic engineering complexity increases
Solution Approach 1:
The patent divides the therapeutic system into two functional components: (1) bacteria genetically engineered to produce and secrete 2'3'-cGAMP, and (2) host animals that receive the bacteria and experience STING pathway activation. This segmentation allows the complex genetic engineering to be confined to the bacterial system, while the animal system remains simple and uses its endogenous STING pathway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NTase05 enzymes enable the production of 2′3′-cGAMP, which can be used as a STING agonist to activate the STING pathway independently of cGAS, providing a therapeutic option for immune response activation.
Implementation Method 1
The synthesis of 2′3′-cGAMP is achieved through the action of nucleotidyltransferase (NTase05) enzymes, which catalyze the production from ATP and GTP components
Data Source
AI summary
Systems, methods, and compositions for the synthesis of 2′3′-cGAMP.